Answers are grounded in this paper and cite their sources.
Background This study evaluated changes in metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus, liver volume, liver/pancreas fat in patients after obesity surgery. Methods Magnetic Resonance Imaging (MRI) measured liver volume/fat and pancreas fat in 31 patients with laparoscopic sleeve gastrectomy (LSG, N = 20) or Roux-en-Y gastric bypass (RYGB, N = 11) preoperatively and at 3- and 12-month follow-up. Clinical data and blood values were taken concomitantly to calculate Non-alcoholic fatty liver disease (NAFLD) score. Results The percentage total weight lost (17.5 % ± 5.4 % at 3 months, 28.4 % ± 8.3 % at 12 months) and percentage excess weight lost (40.0 % ± 11.8 % at 3 months, 65.0 % ± 18.8 % at 12 months) were significant. Liver volume decreased from 2378.3 ± 514.5 cm 3 to 1928.7 ± 333.5 cm 3 at 3 months ( p < 0.001) and 1685.0 ± 310.9 cm 3 at 12 months ( p < 0.001) after surgery. Liver fat percentage decreased from 16.7 % ± 10.3 % to 8.7 % ± 5.4 % at 3 months (p < 0.001) and 5.2 % ± 3.6 % at 12 months (p < 0.001). Pancreatic fat percentage showed a reduction from 14.8 % ± 5.5 % to 10.9 % ± 4.9 % at 3 months ( p = 0.007) postoperatively. NAFLD score improved from preoperative measurements to 12 months postoperatively (−0.89 ± 1.54 vs. -1.77 ± 1.25, p < 0.019). Preoperatively, 22 of 31 (71 %) patients had advanced/intermediate scores; 12 months postoperatively only 12 (39 %) remained ( p = 0.044). No significant differences between LSG and RYGB were found regarding goal parameters. Conclusion Obesity surgery reduced liver volume, type 2 diabetes, fat content of liver and pancreas and improved indicators of MASLD. No significant difference in outcome between operation methods could be established.
No takes yet. Share an insight, caveat, or question.
Kenngott et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: